View Older Stories View More Recent Stories
-
Supreme Court Braidwood ruling is positive for DX names like DHR, EXAS, NTRA, HOLX, QDEL - RBC Capital
-
Supreme Court Braidwood ruling is positive for Exact Sciences (EXAS) and Hologic (HOLX)
-
Supreme Court Braidwood ruling positive for Guardant Health (GH) and Exact Sciences (EXAS) - Barclays
-
'SCOTUS Ruling on Braidwood EXACT-ly What Was Needed' for Exact Sciences (EXAS) - Leerink Partners
-
Exact Sciences (EXAS) call put ratio 1 call to 1.4 puts as share price up 4.3%
-
Exact Sciences (EXAS), Gilead Sciences (GILD) Spike Higher
-
Craig-Hallum would buy Exact Sciences (EXAS) on any weakness today tied to Supreme Court decision
-
TD Cowen's Best Smidcap Ideas 2025
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
Exact Sciences (EXAS) Misses Q1 EPS by 21c, Updates Guidance
-
Mizuho Starts Exact Sciences (EXAS) at Outperform
-
Benchmark Reiterates Buy Rating on Exact Sciences (EXAS)
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Stifel Reiterates Buy Rating on Exact Sciences (EXAS)
-
TD Cowen on Exact Sciences (EXAS): 'Guide Looks Conservative With Multiple Upside Drivers'
-
Exact Sciences (EXAS) PT Lowered to $65 at BTIG
-
Exact Sciences (EXAS) Tops Q4 EPS by 27c, Offers Guidance
-
OTR Global Said to Have Changed 'Read' on Exact Sciences (EXAS), Specialty Channel-Checks Deteriorate (Downgrade) to Mixed
-
Dentsply Sirona (XRAY) appooints new board members
-
Barclays Starts Exact Sciences (EXAS) at Overweight
-
Exact Sciences (EXAS): New Evidence Validates Oncodetect's Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
-
This is the healthcare stock to own for 2025: Jefferies
-
CFRA Upgrades Exact Sciences (EXAS) to Buy, 'we think current valuations offer an attractive entry point'
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Exact Sciences (EXAS) PT Raised to $75 at BTIG
-
Exact Sciences (EXAS) PT Raised to $86 at TD Cowen
-
Piper Sandler Reiterates Overweight Rating on Exact Sciences (EXAS)
-
Leerink Partners on Exact Sciences (EXAS): 'Cologuard Plus Pricing Higher vs. Expectations; EXAS Unlikely to Pursue ADLT'
-
Bernstein SocGen Group Reiterates Outperform Rating on Exact Sciences (EXAS)
-
Stifel on Exact Sciences (EXAS): 'CDLT Rate Up 16% for Cologuard Plus; A Stab At What That Means for FY25 ASP'
-
Wolfe Research on Exact Sciences (EXAS): 'Cologuard Plus CLFS Rate Set At $592; Potential for ~$50MM Upside To '25 Revenue'
-
Exact Sciences (EXAS) Unveils Data Showing Promise of Multi-Cancer Early Detection
-
Exact Sciences (EXAS) PT Lowered to $82 at TD Cowen
-
Piper Sandler Reiterates Overweight Rating on Exact Sciences (EXAS)
-
Exact Sciences (EXAS) PT Lowered to $65 at Benchmark
-
Exact Sciences (EXAS) PT Lowered to $67 at Baird
-
Exact Sciences (EXAS) PT Lowered to $65 at BTIG
-
Stocks expected to have increasing option volume: EXAS SMCI MCHP EXAS FYBR GMED QLYS RVLV LYFT GO CVS
-
After-hours movers: Super Micro Computer, Exact Sciences, Trump Media & Technology
-
Exact Sciences (EXAS) Misses Q3 EPS by 1c, Lowers Guidance
-
Exact Sciences (EXAS) PT Raised to $95 at Canaccord Genuity
-
BTIG Reiterates Buy Rating on Exact Sciences (EXAS)
-
Leerink Partners Reiterates Outperform Rating on Exact Sciences (EXAS)
-
Exact Sciences (EXAS) Announces FDA Approval of Cologuard Plus Test
-
TD Cowen Reiterates Buy Rating on Exact Sciences (EXAS)
-
Canaccord Genuity Reiterates Buy Rating on Exact Sciences (EXAS)
-
Exact Sciences (EXAS) PT Raised to $82 at BTIG
-
Citi Reiterates Buy Rating on Exact Sciences (EXAS)
-
Guardant Health (GH) Weakness Said to be Tied to Data From Exact Sciences (EXAS)
-
Exact Sciences (EXAS) Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024

